Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Lenexa, Kansas 66219


Purpose:

This non-randomized, multi-center, open-label study will evaluate the pharmacokinetics and the safety and tolerability of danoprevir (RO5190591) and ritonavir in healthy volunteers and patients with mild, moderate or severe hepatic impairment. Participants will be administered repeated daily doses of danoprevir and ritonavir. The anticipated time on study treatment is 10 days.


Criteria:

Inclusion Criteria: Healthy Volunteers: - Adult healthy volunteers, 18-70 years of age - Weight >/=50.0 kg - Body Mass Index (BMI) 18.0-40.0 kg/m2 - Ability and willingness to abstain from alcohol-containing beverages or food from 48 hours prior to entry in the clinical study center until discharge - Ability and willingness to abstain from grapefruit or grapefruit juice, star fruit, and Seville oranges from 7 days prior to entry in the clinical study center until discharge - Medical history without major recent or ongoing pathology Patients with hepatic impairment: - Adult patients, 18-70 years of age - Weight >/=50.0 kg - Body Mass Index (BMI) 18.0-40.0 kg/m2 - Ability and willingness to abstain from alcohol-containing beverages or food from 48 hours prior to entry in the clinical study center until discharge - Ability and willingness to abstain from grapefruit or grapefruit juice, star fruit, and Seville oranges from 7 days prior to entry in the clinical study center until discharge - Stable, mild, moderate, or severe liver disease of cryptogenic, post-hepatic, hepatitis B or alcoholic origin Exclusion Criteria: Healthy Volunteers: - Pregnant or lactating women and male partners of women who are pregnant or lactating - Uncontrolled treated/untreated hypertension (systolic blood pressure >/=160 mmHg and /or diastolic blood pressure >/=105 mmHg - Any history of clinically significant cardiovascular or cerebrovascular disease - Creatinine clearance </=60 mL/min - Positive test results for drugs or alcohol - Donation or loss of blood over 450 ml within 60 days prior to screening Patients with hepatic impairment: - Pregnant or lactating women and male partners of women who are pregnant or lactating - Uncontrolled treated/untreated hypertension (systolic blood pressure >/=160 mmHg and /or diastolic blood pressure >/=105 mmHg - Any history of clinically significant cardiovascular or cerebrovascular disease - Severe ascites at screening or admission to the clinic - History of or current severe hepatic encephalopathy (grade 3 or higher) - Any evidence of progressive liver disease within the last 4 weeks - History of liver transplantation - Creatinine clearance </=60 mL/min - Positive test results for drugs or alcohol - Donation or loss of blood over 450 ml within 60 days prior to screening


NCT ID:

NCT01185873


Primary Contact:

Study Director
Clinical Trials
Hoffmann-La Roche


Backup Contact:

N/A


Location Contact:

Lenexa, Kansas 66219
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.